DigestRedComo funciona
Red
/
Empresas
Fo
No verificado

Forlong Biotechnology

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

12 Comunicados de prensa

Ver todos los comunicados de prensa
04/08/2026
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Forlong Biotechnology Announces Approval to Initiate Phase I Clinical Trial of FL115 (IL-15 Superagonist) Subcutaneous Injection in Australia
Fuente
Forlong Biotechnology
Editor
Business Wire
1.00
0
03/08/2026
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Forlong Biotechnology Announces Successful Completion of GMP Pivotal Batch Production for FL115 (IL-15 Superagonist), Ready to Support Upcoming Phase III Clinical Trial in Non-Muscle Invasive Bladder Cancer (NMIBC)
Fuente
Forlong Biotechnology
Editor
Business Wire
1.00
0
27/05/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Forlong Announces Completion of Phase I Clinical Studies of FL115 Monotherapy (IV): Disease Control for 3 Heavily-pretreated Patients with Advanced Solid Tumors over 12 Months
Fuente
Forlong Biotechnology
Editor
Business Wire
1.00
0
19/05/2026
Oncología
Asociaciones/Profesionales
Salud
Finanzas
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Forlong Raises Approximately 120 Million RMB in Series Pre-B Financing to Advance its IL-15 and IL-18 Pipeline
Fuente
Forlong Biotechnology
Editor
Business Wire
1.00
0
21/04/2026
Ferias y Congresos
Análisis de Mercados
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Forlong Biotechnology to Present Clinical Data from the First-in-human Study for FL115 (IL-15 Superagonist) in US Patients with Advanced Solid Tumors at 2026 ASCO Annual Meeting
Fuente
Forlong Biotechnology
Editor
Business Wire
1.00
0
15/04/2026
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC)
Fuente
Forlong Biotechnology
Editor
Business Wire
1.00
0
17/03/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Forlong Biotechology to Present Preclinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, and FL116, a PD-1/interleukin-18 (IL-18) bispecific antibody, at the 2026 AACR Annual Meeting
Fuente
Forlong Biotechnology
Editor
Business Wire
1.00
0
07/01/2026
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and Acceptance of IND for FL115 Subcutaneous Injection by NMPA
Fuente
Forlong Biotechnology
Editor
Business Wire
1.00
0
30/10/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
Forlong Biotechology to Present Clinical Data from FL115, a novel interleukin-15 (IL-15) superagonist, in Late-breaking Session at 40th SITC Annual Meeting
Fuente
Forlong Biotechnology
Editor
Business Wire
1.00
0
30/10/2025
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Forlong Dosed First Patient in Phase 2 Clinical Trial of FL115, a novel interleukin-15 (IL-15) superagonist, for nonmuscle invasive bladder cancer (NMIBC)
Fuente
Forlong Biotechnology
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0